Image Protect, Inc. Unveils Strategic Growth Vision with InterceptCS™ Cold Sore Prevention System

Image Protect, Inc. (OTC: IMTL) has provided an update on its strategic growth vision and long-term revenue objectives, focusing on its InterceptCS™ Cold Sore Prevention System. The system, classified as a Class II Medical Device by Health Canada, offers a non-drug, clinically tested solution for preventing cold sores during the prodrome stage. With an estimated global market size exceeding $3.5 billion annually, the company sees significant opportunity for InterceptCS™ in addressing consumer needs.

The company is implementing a multi-channel sales strategy, including direct-to-consumer and third-party platforms like Amazon, Walmart.com, and eBay, to enhance accessibility and consumer adoption. Image Protect aims to achieve up to $100 million in annual revenue within five years, driven by device sales and recurring purchases of thermal activators. This goal is supported by a diverse marketing plan encompassing social media campaigns, paid advertising, and influencer outreach.

Frank Casella, CEO of Global Wellness Products, emphasized the potential of InterceptCS™ in addressing a large, underserved market and the importance of building a strong recurring revenue model. The company is also developing a new multi-use thermal activator to reduce consumer costs and improve profit margins. With regulatory approval from Health Canada and a growing ecommerce infrastructure, Image Protect is committed to establishing InterceptCS™ as a globally recognized brand in personal wellness.